> FILE REG
FILE 'REGISTRY' ENTERED AT 17:21:41 ON 22 JUL 2010

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2010 HIGHEST RN 1233453-03-6
DICTIONARY FILE UPDATES: 21 JUL 2010 HIGHEST RN 1233453-03-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading 10588166.str



chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
chain bonds :
1-12 4-11 6-7 7-8 7-9 7-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-12 2-3 3-4 4-5 4-11 5-6 6-7 7-8 7-9 7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS

Uploading LL5.str



chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
chain bonds :
1-12 4-11 6-7 7-8 7-9 7-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-12 4-11 6-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-9 7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS

AUTHOR SEARCH

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 17:21:44 ON 22 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Jul 2010 VOL 153 ISS 4
FILE LAST UPDATED: 21 Jul 2010 (20100721/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

```
This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D STAT QUE L33
L24         2346 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L25          205 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L26           71 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L27         2879 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L28            1 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L33            5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L24 AND ((L25 OR L26
                  OR L27 OR L28))


=> FILE WPIX
FILE 'WPIX' ENTERED AT 17:21:54 ON 22 JUL 2010
COPYRIGHT (C) 2010 THOMSON REUTERS

FILE LAST UPDATED:          21 JUL 2010   <20100721/UP>
MOST RECENT UPDATE:           201046      <201046/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.6 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
    and FI-Terms have been updated with reclassifications to
    end of March 2010.
    No update date (UP) has been created for the reclassified
    documents, but they can be identified by
    specific update codes (see HELP CLA for details) <<<

>>> FOR THE LATEST DERWENT WORLD PATENTS INDEX (DWPI)
    STN USER DOCUMENTATION, PLEASE VISIT:
    http://www.stn-international.com/stn_dwpi.html <<<

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> For changes in DWPI see HELP CHANGE - last updated April 6, 2010 <<<

>>> New display format ALLSTR available - see NEWS  <<<

>>> US National Patent Classification thesaurus added - see NEWS <<<

=> D STAT QUE L52
L41          113 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L42           21 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L43           13 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L44          142 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L45            8 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L48            2 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L41 AND ((L42 OR L43 OR
                  L44 OR L45))
L49            1 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L42 AND ((L43 OR L44 OR
                  L45))
L50            1 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L43 AND ((L44 OR L45))
L52            2 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50)


=> DUP REMOVE L33 L52
FILE 'HCAPLUS' ENTERED AT 17:22:10 ON 22 JUL 2010
```

FILE 'WPIX' ENTERED AT 17:22:10 ON 22 JUL 2010

PROCESSING COMPLETED FOR L33
PROCESSING COMPLETED FOR L52
L60 7 DUP REMOVE L33 L52 (0 DUPLICATES REMOVED)
ANSWERS '1-5' FROM FILE HCAPLUS
ANSWERS '6-7' FROM FILE WPIX

=> D L60 IBIB ABS HITIND HITSTR 1-5; D L60 IBIB AB HITSTR 6-7

L60 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:331043 HCAPLUS Full-text
DOCUMENT NUMBER: 148:547206
TITLE: Synthesis and structural characteristics of highly graphitized carbon nanofibers produced from the catalytic decomposition of ethylene: Influence of the active metal (Co, Ni, Fe) and the zeolite type support
AUTHOR(S): Romero, Amaya; Garrido, Agustin; Nieto-Marquez, Antonio; Sanchez, Paula; de Lucas, Antonio; Valverde, Jose Luis
CORPORATE SOURCE: Facultad de Ciencias Quimicas/Escuela Tecnica Agricola, Universidad de Castilla-La Mancha, Ciudad Real, 13071, Spain
SOURCE: Microporous and Mesoporous Materials (2008), 110(2-3), 318-329
CODEN: MIMMFJ; ISSN: 1387-1811
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In order to study the influence of the metal phase in the carbon yield and structural characteristics of carbon nanofibers (CNFs) synthesized by CVD over supported catalysts, different catalysts were prepared using iron, cobalt and nickel as active metal and zeolites Y and mordenite as support. The results showed that the metal precursor produced a great influence on the catalytic activity, fact that could be explained in according to the different solubility of carbon in the metals or in the differences in the diffusion and segregation of carbon through the metal particles. Characterization data of the solid carbon products revealed unique structures and textural properties as well as crystalline conditions on function of metal used. Addnl., support-metal interaction was evaluated, where expts. with similar nickel load over Y and mordenite zeolites were carried out, finding higher carbon yields and more ordered structures when Y zeolite was used.
CC 67-3 (Catalysis, Reaction Kinetics, and Inorganic Reaction Mechanisms)
Section cross-reference(s): 66, 75
OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1032532 HCAPLUS Full-text
DOCUMENT NUMBER: 143:464206
TITLE: Growth of Carbon Nanofibers from Ni/Y Zeolite Based Catalysts: Effects of Ni Introduction Method, Reaction Temperature, and Reaction Gas Composition
AUTHOR(S): de Lucas, Antonio; Garrido, Agustin; Sanchez, Paula; Romero, Amaya; Valverde, Jose L.

CORPORATE SOURCE: acultad de Ciencias Quimicas y Escuela Tecnica Agricola, Departamento de Ingenieria Quimica, Universidad de Castilla La Mancha, Ciudad Real, 13071, Spain
SOURCE: Industrial & Engineering Chemistry Research (2005), 44(22), 8225-8236
CODEN: IECRED; ISSN: 0888-5885
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Results of thorough studies of the catalytic synthesis of carbon nanofibers (CNFs) by the decomposition of ethylene using Y zeolite as the support and Ni as the active phase were discussed. Exptl. results clearly indicated that the metal-incorporation method (ion exchange or impregnation) had very significant effects not only on CNFs growth but also on the deactivation rate, the final yield of CNFs, and the characteristics of the synthesized CNFs. CNFs synthesized from the impregnated catalyst grew from small and well-dispersed Ni particles anchored to the outer surface of the zeolite. Nevertheless, CNFs synthesized from the ion-exchanged catalyst grew from Ni particles (of very small size) lodged inside the pore system of the zeolite. Reaction temperature and C2H4/H2 (volume/volume) had a considerable effect on both carbon yield and CNFs morphol. Two types of CNFs were observed as a function of the reaction temperature: "fishbone structures" at temps. below 600° C and "tubular structures" at temps. above 600° C. On the other hand, as the C2H4/H2 ratio was decreased, the CNFs became slightly more graphitic in nature and the arrangement of graphite sheets changed from the fishbone structure to "octopus carbon".

CC 57-8 (Ceramics)
Section cross-reference(s): 78

OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:347304 HCAPLUS Full-text
DOCUMENT NUMBER: 139:56904
TITLE: Characterization and Catalytic Properties of Titanium-Pillared Clays Prepared at Laboratory and Pilot Scales: A Comparative Study
AUTHOR(S): Valverde, Jose L.; De Lucas, Antonio; Dorado, Fernando; Sun-Kou, Rosario; Sanchez, Paula; Asencio, Isaac; Garrido, Agustin; Romero, Amaya
CORPORATE SOURCE: Departamento de Ingenieria Quimica Facultad de Quimicas, Universidad de Castilla-La Mancha, Ciudad Real, 13004, Spain
SOURCE: Industrial & Engineering Chemistry Research (2003), 42(12), 2783-2790
CODEN: IECRED; ISSN: 0888-5885
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The textural and structural characteristics and the acid properties of Ti-pillared montmorillonites prepared at bench scale (1 kg per batch level) have been compared with those prepared at laboratory scale (a few grams). The pillared clays have been examined by X-ray diffraction and characterized by different techniques and methods including nitrogen sorption isotherms, temperature-programmed desorption/reduction, and atomic absorption. The catalytic performance was evaluated by means of the selective reduction of NO by propylene over Cu2+ ion-exchanged samples. The differences of the textural characteristics between the laboratory and pilot samples did not significantly affect the catalytic results.

CC 59-3 (Air Pollution and Industrial Hygiene)
Section cross-reference(s): 67
OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:29927 HCAPLUS Full-text
DOCUMENT NUMBER: 134:265289
TITLE: Quality of olive oil. III. Application of near-infrared spectroscopy (NIRS) to the quality control of olive oil
AUTHOR(S): Garrido, A.; Sanchez Pineda de las Infantas, M. T.; Cobo, C.
CORPORATE SOURCE: Depto. de Produccion Animal, Univ. de Cordoba, Spain
SOURCE: Alimentacion, Equipos y Tecnologia (2000), 19(7), 165-170
CODEN: AEQTDY; ISSN: 0212-1689
PUBLISHER: Editorial Alcion, S.A.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Spanish
AB A review with 41 refs. The topics include current status of olive oil anal. and quality control, principles and instrumentation of NIRS, qual. and quant. anal. of olive oil by NIRS, and broader anal. applications to the anal. of oils and fats.
CC 17-0 (Food and Feed Chemistry)
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:556213 HCAPLUS Full-text
DOCUMENT NUMBER: 134:70432
TITLE: Olive oil quality. I. Concepts and analytical and sensorial parameters of quality
AUTHOR(S): Sanchez Pineda, M. T.; Garrido, A. ; Cobo, C.
CORPORATE SOURCE: Dpt. de Bromatologia y Tecnologia de los Alimentos, Universidad de Cordoba, Spain
SOURCE: Alimentacion, Equipos y Tecnologia (2000), 19(5), 63-69
CODEN: AEQTDY; ISSN: 0212-1689
PUBLISHER: Editorial Alcion, S.A.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Spanish
AB A review with 21 refs. on the concept of olive oil quality, parameters of oil quality determined by traditional physicochem. methods, and olive oil quality parameters determined by organoleptic anal.
CC 17-0 (Food and Feed Chemistry)
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 6 OF 7 WPIX COPYRIGHT 2010 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-D99595 [200828] WPIX
CROSS REFERENCE: 2008-E49165; 2008-E61270; 2008-G33820; 2008-L13777
DOC. NO. CPI: C2008-131560 [200828]
TITLE: Use of dihydroxybenzene compound to treat e.g. hemangiomas, hemangioblastomas, benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle

and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis

DERWENT CLASS: B05

INVENTOR: ANGULO FRUTOS J; CUEVAS SANCHEZ P; GIMENEZ GALLEGO G; LOZANO PUERTO R M; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; VALVERDE LOPEZ S; LOPEZ S V; FERNANDEZ JAEN T F; FRUTOS J A; MORENO NUNCIO F J; RIVAS LOPEZ L I; SANCHEZ P C

PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL

COUNTRY COUNT: 120

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020034	A1	20080221	(200828)*	EN	101	[22]
US 20080114063	A1	20080515	(200835)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020034	A1	WO 2007-EP58447	20070815
US 20080114063	A1	US 2007-839529	20070815

PRIORITY APPLN. INFO: ES 2007-1855 20070702
ES 2006-2217 20060816

AB WO 2008020034 A1 UPAB: 20080501

NOVELTY - Use of a 2,5-dihydroxybenzene compound (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.

DETAILED DESCRIPTION - Use of a 2,5-dihydroxybenzene compound of formula (I) or its salt, solvate, isomer or prodrug in the manufacturing of a medicament for the treatment and/or prophylaxis of a disease of hemangiomas and hemangioblastomas, is claimed.

R1 = -(CH2)aY1 or -CH=CH-(CH2)pY1;

Y1 = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ or -CO2R3;

X+ = organic cation or inorganic cation such that general charge of (I) is neutral;

R9, R9a = -OH or -OR2;

R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R3 = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

ACTIVITY - Cytostatic; Gastrointestinal-Gen; Antiinflammatory; Antiasthmatic; Muscular-Gen; Osteopathic; Antiulcer; Protozoacide; Analgesic; Antiarthritic.

MECHANISM OF ACTION - None given.

USE - (I) is useful for treating/preventing a disease of hemangiomas and hemangioblastomas (claimed), benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis (proctitis, proctosigmoiditis and pancolitis), leishmaniasis, pain and arthritis. The ability of (I) to treat muscle lesion was tested in a patient. The result showed that the patient (taken 500 mg of 2,5-dihydroxybenzene sulfonic acid for two weeks) recovered from the lesion in the quadriceps and the hematoma was not observed.

ADVANTAGE - (I) is safe and effective for treating leishmaniasis. (I) exhibits pharmacological properties.

L60 ANSWER 7 OF 7 WPIX COPYRIGHT 2010 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-F85649 [200837] WPIX

CROSS REFERENCE: 2008-G33818; 2008-G33819; 2008-G33821; 2008-L13776
DOC. NO. CPI: C2008-188857 [200837]
TITLE: Use of 2,5-dihydroxybenzene derivatives to prepare a medicament for the therapeutic and/or prophylactic treatment of e.g. skin cancer, prostate cancer, thyroid cancer, hematological dyscrasias and fibrosis (e.g. endomyocardial fibrosis)
DERWENT CLASS: B05
INVENTOR: ROMERO GARRIDO A; ANGULO FRUTOS J; CUEVAS SANCHEZ P; GIMENEZ GALLEGO G; LOZANO PUERTO R M; MORGAN I S D T; ROMERO GARRIDO A; SAENZ DE TEJADA GORMAN I; SAENZ DE TEJADA MORGAN I; VALVERDE LOPEZ S; VAVERDE LOPEZ S; DE TEJADA M I S; FRUTOS J A; GALLEGO G G; GARRIDO A R; LOPEZ S V; LOZANO P R M; SANCHEZ P C
PATENT ASSIGNEE: (ACTI-N) ACTION MEDICINES SL; (ACTI-N) ACTION MEDICINES
COUNTRY COUNT: 120

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008020027	A2	20080221	(200837)*	EN	86[15]	
US 20080113947	A1	20080515	(200837)	EN		
US 20080113948	A1	20080515	(200837)	EN		
US 20080114060	A1	20080515	(200837)	EN		
WO 2008020027	A3	20080410	(200837)	EN		
US 20080125486	A1	20080529	(200838)	EN		
ES 2315118	A1	20090316	(200922)	ES		
ES 2315118	B1	20091230	(201004)	ES		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008020027	A2	WO 2007-EP58440	20070815
ES 2315118	A1	ES 2006-2218	20060816
US 20080113947	A1	US 2007-839515	20070815
US 20080113948	A1	US 2007-839520	20070815
US 20080114060	A1	US 2007-839522	20070815
US 20080125486	A1	US 2007-839525	20070815
ES 2315118	B1	ES 2006-2218	20060816

PRIORITY APPLN. INFO: ES 2007-1856 20070702
ES 2006-2218 20060816

AB WO 2008020027 A2 UPAB: 20090407
NOVELTY - Use of 2,5-dihydroxybenzene derivatives (I) and their salts, solvate, isomer or prodrug to prepare a medicament for the therapeutic and/or prophylactic treatment of skin cancer, is claimed.

DETAILED DESCRIPTION - Use of a 2,5-dihydroxybenzene derivatives of formula (I) and their salts, solvate, isomer or prodrug to prepare a medicament for the therapeutic and/or prophylactic treatment of skin cancer, is claimed.

R1 = -(CH2)aY1 or -CH=CH-(CH2)pZ;

Y1 = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3;

Z = -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ or -CO2R3;

X+ = organic cation or inorganic cation, such that the general charge of the compound is neutral;

R9, R9a = OH or OR2;

R2 = alkyl, aryl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl or arylcarbonyl (all optionally substituted);

R3 = alkyl or aryl (both optionally substituted); and

a, p = 0-6.

Provided that: when Y1 is -SO3H, -SO3-.X+ or -SO3R3, then R9, R9a are OH or OR2; at least one of R9, R9a is alkylsulfonyloxy, arylsulfonyloxy, alkylcarbonyloxy or arylcarbonyloxy (all optionally substituted); and when R9, R9a are both OR2, then R9, R9a can be the same or different.

ACTIVITY - Cytostatic; Antianemic; Immunostimulant; Antiinflammatory.

MECHANISM OF ACTION - Fibroblast mitogenesis inhibitor.

USE - (I) are useful to treat skin cancer such as lentigo maligna, melanoma, keratoacanthoma, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, sarcoma, angiosarcoma, cutaneous lymphoma, sweat gland carcinoma and sebaceous gland carcinoma (claimed). (I) are useful to treat hematological dyscrasias, myelodysplastic syndromes or fibrosis (e.g. endomyocardial fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis, progressive massive fibrosis and renal interstitial fibrosis). (I) are useful for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. (I) is useful for the treatment/prophylaxis of cancer of an organ (e.g. breast cancer, bladder cancer, colon cancer, rectal cancer, kidney cancer, lung cancer, cervical cancer, prostate cancer, brain cancer, testicular cancer, thyroid cancer and ovarian cancer). The ability of (I) to treat prostate cancer was tested in mice. The result showed that the percentage of control of prostate cancer by 2,5-diacetoxybenzene sulfonate was 85% and 72%, at 1 mu M and 5 mu M, respectively.

ADVANTAGE - (I) are effective for treating fibrosis and cancer.

STRUCTURE SEARCH

=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 17:22:51 ON 22 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

=> D STAT QUE L23
L2 STR



NODE ATTRIBUTES:
HCOUNT IS M1 AT 10
HCOUNT IS M1 AT 11
HCOUNT IS M1 AT 12
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS C AT 7
NSPEC IS C AT 8
NSPEC IS C AT 9
NSPEC IS C AT 10
NSPEC IS C AT 11
NSPEC IS C AT 12
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 7 8 9 10 11 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L4 575 SEA FILE=REGISTRY SSS FUL L2
L5 STR




```
NODE ATTRIBUTES:
HCOUNT  IS M1     AT  10
HCOUNT  IS M1     AT  11
HCOUNT  IS M1     AT  12
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   7  8  9 10 11 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L7          569 SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L8         1313 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L7
L9        21558 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT/CT OR
                (?PSORIASIS? OR ?PUSTULOSIS?)/BI
L10           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L8 AND L9
L11         553 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L8 AND ((BAC OR DMA
                OR PAC OR PKT OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR
                ?TREAT?)/BI)
L12           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L11 AND L9
L13           6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L10 OR L12
L14           1 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  "2,5-DIHYDROXYBENZENE
                SULFONIC ACID"/CN
L15         181 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L14
L16          68 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L15 AND ((BAC OR DMA
```

```
                OR PAC OR PKT OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR
                ?TREAT?)/BI)
L17             5 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L16 AND L9
L18             6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L13 OR L17
L19             4 SEA FILE=REGISTRY SPE=ON  ABB=ON  PLU=ON  ("2,5-DIHYDROXYBENZEN
                ESULFONIC ACID CALCIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONI
                C ACID DIETHYLAMINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC
                ACID MONOSODIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                MONOTOSYLATE MORPHOLINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFON
                IC ACID SODIUM SALT"/CN)
L20           494 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L19
L21           359 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L20 AND ((BAC OR DMA
                OR PAC OR PKT OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR
                ?TREAT?)/BI)
L22             4 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L21 AND L9
L23             6 SEA FILE=HCAPLUS SPE=ON  ABB=ON  PLU=ON  L22 OR L18


=> S L23 NOT L33
L61             6 L23 NOT L33

=> FILE WPIX
FILE 'WPIX' ENTERED AT 17:23:02 ON 22 JUL 2010
COPYRIGHT (C) 2010 THOMSON REUTERS

FILE LAST UPDATED:          21 JUL 2010   <20100721/UP>
MOST RECENT UPDATE:           201046      <201046/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.6 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
    and FI-Terms have been updated with reclassifications to
    end of March 2010.
    No update date (UP) has been created for the reclassified
    documents, but they can be identified by
    specific update codes (see HELP CLA for details) <<<

=> D STAT QUE L40
L5              STR
```



```
NODE ATTRIBUTES:
HCOUNT  IS M1     AT  10
HCOUNT  IS M1     AT  11
HCOUNT  IS M1     AT  12
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   7  8  9 10 11 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L38          31 SEA FILE=WPIX SSS FUL L5
L39          99 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L38/DCR
L40           4 SEA FILE=WPIX SPE=ON  ABB=ON  PLU=ON  L39 AND (?PSORIASIS? OR
                ?PUSTULOSIS?)


=> S L40 NOT L52
L62           4 L40 NOT L52

=> DUP REMOVE L61 L62
FILE 'HCAPLUS' ENTERED AT 17:23:38 ON 22 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 17:23:38 ON 22 JUL 2010
COPYRIGHT (C) 2010 THOMSON REUTERS
PROCESSING COMPLETED FOR L61
PROCESSING COMPLETED FOR L62
L63           8 DUP REMOVE L61 L62 (2 DUPLICATES REMOVED)
                ANSWERS '1-6' FROM FILE HCAPLUS
                ANSWERS '7-8' FROM FILE WPIX

L63  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2010 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2008:221788  HCAPLUS  Full-text
DOCUMENT NUMBER:          148:276732
TITLE:                    Use of 2,5-dihydroxybenzene derivatives for the
                          treatment of arthritis and pain
INVENTOR(S):              Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo;
                          Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier;
                          Lozano Puerto, Rosa Maria; Romero Garrido, Antonio;
                          Valverde Lopez, Serafin
PATENT ASSIGNEE(S):       Action Medicines, S.L., Spain
SOURCE:                   PCT Int. Appl., 134pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
```

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020033	A1	20080221	WO 2007-EP58446	20070815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2315117	A1	20090316	ES 2006-2217	20060816
ES 2315117	B1	20091230		
US 20080114063	A1	20080515	US 2007-839529	20070815
EP 2054045	A1	20090506	EP 2007-788431	20070815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:
ES 2006-2217 A 20060816
ES 2007-1855 A 20070702
WO 2007-EP58446 W 20070815

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 148:276732

AB The present invention relates to the use of 2,5-dihydroxybenzene derivs. or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.

IPCI A61K0031-10 [I,A]; A61K0031-095 [I,C*]; A61K0031-192 [I,A]; A61K0031-185 [I,C*]; A61P0019-02 [I,A]; A61P0019-00 [I,C*]; A61K0031-618 [I,A]; A61K0031-60 [I,A]
IPCR A61K0031-095 [I,C]; A61K0031-10 [I,A]; A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0031-618 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]
CC 1-7 (Pharmacology)
Section cross-reference(s): 63
ST hydroxybenzene deriv arthritis pain therapy
IT Hepatocyte growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Angiogenesis
(corneal; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Blood vessel, neoplasm
(hemangioblastoma; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Respiratory system disease
(hyperresponsiveness; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Helicobacter pylori
(infection; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Pharmaceutical injections
(intraarticular; use of hydroxybenzene derivs. for treatment

of arthritis and pain)
IT Protozoacides
(leishmanicides; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Skeletal muscle
(lesions; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Arthritis
(lupus-related, psoriasis-related, infectious, viral, parasitic, bacterial; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Fibroblast
(mitogenesis; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Leukotrienes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modifiers; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Arthritis
(polyarthritis; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Disease, animal
(pterygium; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Proliferation inhibition
(retinal endothelial; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Interleukin receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solubilized; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Pharmaceutical emulsions
Topical drug delivery systems
(topical lotions; use of hydroxybenzene derivs. for treatment of arthritis and pain)
IT Analgesics
Anesthetics
Angiogenesis inhibitors
Anti-inflammatory agents
Antiandrogens
Antiarthritics
Antiasthmatics
Antibiotics
Antioxidants
Antirheumatic agents
Antitumor agents
Asthma
Buccal drug delivery systems
Cholinergic antagonists
Crohn disease
Endometriosis
Gastroenteritis
Gout
Hemangioma
Human
Immunomodulators
Immunosuppressants
Inhalation drug delivery systems
Leishmaniasis
Neuroglia, neoplasm

Nonsteroidal anti-inflammatory drugs
Ophthalmic drug delivery systems
Oral drug delivery systems
Osteoarthritis
Otic drug delivery systems
Pain
Parasiticides
Parenteral drug delivery systems
Pharmaceutical creams
Pharmaceutical gels
Pharmaceutical solids
Pharmaceutical solutions
Prodrugs
Prophylaxis
Rectal drug delivery systems
Rheumatoid arthritis
Topical drug delivery systems
Transdermal drug delivery systems
Ulcerative colitis
Vaginal drug delivery systems
α-Adrenoceptor antagonists
β-Adrenoceptor agonists
(use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT Corticosteroids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT 7440-57-5, Gold, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(i.m.; use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT 9081-34-9, 5-α-Reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT 106096-92-8, FGF-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of hydroxybenzene derivs. for treatment of arthritis and pain)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, 2,5-Dihydroxybenzenesulfonic acid, ester derivs. 636-01-1, 2,5-Dihydroxycinnamic acid 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 28088-64-4D, Aminosalicylic acid, derivs. 51579-69-2 57775-26-5 59687-22-8 60630-38-8 63177-57-1 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treatment of arthritis and

pain)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 88-46-0D, 2,5-Dihydroxybenzenesulfonic acid, ester derivs. 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of hydroxybenzene derivs. for treatment of arthritis and pain)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L63 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:888919 HCAPLUS Full-text
DOCUMENT NUMBER: 143:216719
TITLE: Use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment

of angiodependent diseases such as cancer and psoriasis

INVENTOR(S): Cuevas, Sanchez Pedro

PATENT ASSIGNEE(S): Investread Europa, S.L., Spain

SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2238924	A1	20050901	ES 2004-371	20040217
ES 2238924	B1	20061201		
AU 2005211956	A1	20050825	AU 2005-211956	20050216
CA 2555248	A1	20050825	CA 2005-2555248	20050216
EP 1719509	A1	20061108	EP 2005-708114	20050216
EP 1719509	B1	20091007		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, IS, YU				
CN 101014330	A	20070808	CN 2005-80005187	20050216
JP 2007522256	T	20070809	JP 2006-553602	20050216
AT 444743	T	20091015	AT 2005-708114	20050216
PT 1719509	E	20100113	PT 2005-708114	20050216
ES 2334447	T3	20100310	ES 2005-708114	20050216
IN 2006DN04546	A	20070810	IN 2006-DN4546	20060807
KR 2007007783	A	20070116	KR 2006-716184	20060811
MX 2006009295	A	20070323	MX 2006-9295	20060816
US 20070149618	A1	20070628	US 2006-506469	20060816
US 20080125485	A1	20080529	US 2007-839508	20070815
US 20080293816	A1	20081127	US 2008-588166	20080807
US 20090111779	A1	20090430	US 2008-257854	20081024

PRIORITY APPLN. INFO.:

ES 2004-371	A	20040217
WO 2005-ES70017	W	20050216
US 2006-588166	A2	20060802
ES 2006-2219	A	20060816
US 2006-506469	A2	20060816
ES 2007-1857	A	20070702
US 2008-588166	A2	20080807

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforementioned compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases which present a reduction in apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compds. in non-quiescent

cells. In addition, the invention details the potentiating effect of said compds. on known cytostatic medicines in the treatment of tumors and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compds., based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.

IPCI A61K0031-185 [ICM,7]; A61P0035-00 [ICS,7]; A61P0017-06 [ICS,7]; A61P0017-00 [ICS,7,C*]

IPCR A61K0031-185 [I,C*]; A61K0031-185 [I,A]; A61K0031-21 [I,C*]; A61K0031-255 [I,A]; A61P0017-00 [I,C*]; A61P0017-06 [I,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]

CC 63-6 (Pharmaceuticals)

ST dihydroxybenzenesulfonic acid drug formulation

IT Neoplasm
Psoriasis
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2, 2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 20123-80-2, 2,5-Dihydroxybenzenesulfonic acid calcium salt 862162-74-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of dihydroxybenzenesulfonic acid in drugs for treatment of angiodependent diseases)

RN 88-46-0 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 862162-74-1 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:?) (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L63 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:521020 HCAPLUS Full-text
DOCUMENT NUMBER: 150:487712
TITLE: Methods of use 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido, Antonio; Gimenez Gallego, Guillermo; Valverde Lopez, Serafin; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: U.S. Pat. Appl. Publ., 32pp., Cont.-in-part of U.S. Ser. No. 588,166.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090111779	A1	20090430	US 2008-257854	20081024
ES 2238924	A1	20050901	ES 2004-371	20040217
ES 2238924	B1	20061201		
WO 2005077352	A1	20050825	WO 2005-ES70017	20050216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070149618	A1	20070628	US 2006-506469	20060816
US 20080293816	A1	20081127	US 2008-588166	20080807

PRIORITY APPLN. INFO.:		
ES 2004-371	A	20040217
WO 2005-ES70017	W	20050216
US 2006-506469	A3	20060816
US 2008-588166	A2	20080807
US 2006-588166	A2	20060802

OTHER SOURCE(S): MARPAT 150:487712

GI



AB Methods of use 2,5-dihydroxybenzene sulfonic acid compds. of formula I, where X is a hydrogen, an organic cation or an inorg. cation; n is an integer from 1 to 2; and m is an integer from 1 to 2, for the treatment of cancer, rosacea and psoriasis are disclosed. The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for the treatment of skin cancer, organ cancer and leukemia. Method also involves in improving the efficacy of chemotherapy, radiation therapy and cancer immunotherapy. The invention also provides methods for the treatment of rosacea and psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one other therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.

INCL 514167000; 514576000; 514568000; 514171000

IPCI A61K0031-59 [I,A]; A61K0031-185 [I,A]; A61K0031-192 [I,A]; A61K0031-56 [I,A]; A61P0035-00 [I,A]; A61P0017-00 [I,A]

IPCR A61K0031-59 [I,C]; A61K0031-59 [I,A]; A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-192 [I,A]; A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]

NCL 514/167.000; 514/171.000; 514/568.000; 514/576.000

CC 1-6 (Pharmacology)
Section cross-reference(s): 2, 63

ST dihydroxybenzene sulfonate compd steroid combination therapy cancer rosacea psoriasis; antitumor antiinflammatory antioxidant combination chemotherapy potentiation dihydroxybenzene sulfonate compd

IT Animal cell line
(C-6; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(basal cell carcinoma; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
(basal cell; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Retinoids
Steroids

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Antiproliferative agents
Antitumor agents
Brain, neoplasm
Combination chemotherapy
Erythema
Human
Leukemia
Melanoma
Neoplasm
Neuroglia, neoplasm
Pharmaceutical carriers
Pharmaceutical creams
Psoriasis
Skin, neoplasm
Telangiectasia
Topical drug delivery systems
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Hydrocarbon oils
Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Drug interactions
(potentiation; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, disease
(rosacea, characterized by papules and pustules; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, disease
(rosacea; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT Neuroglia, neoplasm
(s.c.; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 69-72-7, Salicylic acid, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 1406-16-2D, Vitamin D, analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 51-21-8, 5-FU 57-22-7, Vincristine 88-46-0, 2,5-Dihydroxybenzene sulfonic acid 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 15663-27-1, Cisplatin 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 33069-62-4, Paclitaxel 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 97682-44-5, Irinotecan
RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 112-92-5, Stearyl alcohol 36653-82-4, Cetyl alcohol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

IT 88-46-0, 2,5-Dihydroxybenzene sulfonic acid 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of use 2,5-dihydroxybenzene sulfonic acid compds. for treatment of cancer, rosacea and psoriasis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N



CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 20123-80-2 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L63 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1162068 HCAPLUS Full-text
DOCUMENT NUMBER: 149:402057
TITLE: Nitrosated derivatives of 2,5-dihydroxybenzene compounds and their preparation and use in the treatment of diseases
INVENTOR(S): Gimenez Gallego, Guillermo; Saenz De Tejada Gorman, Inigo; Cuevas Sanchez, Pedro; Angulo Frutos, Javier; Valverde Lopez, Serafin
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 147pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008113863	A2	20080925	WO 2008-EP53455	20080324
WO 2008113863	A3	20081211		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: ES 2007-764 A 20070322
ES 2007-2037 A 20070720

OTHER SOURCE(S): CASREACT 149:402057; MARPAT 149:402057

GI



AB The invention relates to nitrosated derivs. of 2,5-dihydroxybenzene compds. of formula I that are useful in the preparation of medicinal products for the treatment of different diseases. The diseases in question are, in particular: cancer, rosacea, psoriasis, fibrosis, hemangiomas, ocular diseases, skin pigmentation and skin hyperpigmentation, diseases associated with amyloidosis, dermatitis, actinic and seborrheic keratosis, erectile dysfunction, female sexual dysfunction, arterial hypertension, atherosclerosis, inflammatory diseases in particular, arthritis, glomerulonephritis and asthma, intestinal inflammatory diseases in particular, ulcerative colitis and Crohn's disease, benign prostatic hyperplasia, Leishmaniasis, angiogenesis associated to chronic temporal lobe epilepsy, pain, hyperlipidemia and thrombosis. Compds. of formula I wherein R1 is (CH2)0-6SO3H and derivs., (CH2)0-6PO3H and derivs., (CH2)0-6CO2H and derivs., CH=CH(CH2)0-6SO3H and derivs., CH=CH(CH2)0-6PO3H and derivs., and CH=CH(CH2)0-6CO2H and derivs.; R9 and R9' are independently OH and derivs. and O-acyl, with the proviso that at least one of R9 and R9' is OH derivative; and their salts, isomers, prodrugs and solvates thereof, are claimed. Example compound II was prepared by esterification of 5-bromovaleric acid with 4-nitrophenol; the resulting 5-bromovaleric acid 4-nitrophenyl ester underwent nitrosation with silver nitrate to give 5-nitrooxyvaleric acid 4-nitrophenyl ester, which underwent sulfonylation and substitution to give compound II. All the invention compds. were evaluated for their FGF-1 inhibitory activity (data given).

IPCI C07C0203-04 [I,A]; C07C0309-24 [I,A]; C07C0309-42 [I,A]; A61K0031-216 [I,A]; A61K0031-215 [I,A]; A61P0035-00 [I,A]; A61P0001-04 [I,A]; A61P0015-10 [I,A]; A61P0015-12 [I,A]; A61P0017-06 [I,A]; A61P0025-08 [I,A]; A61P0019-02 [I,A]; A61P0027-02 [I,A]; A61P0029-00 [I,A]; A61P0007-02 [I,A]; A61P0007-04 [I,A]; A61P0009-12 [I,A]; A61P0009-00 [I,C*]; C07C0203-00 [I,C]; C07C0203-04 [I,A]; A61K0031-21 [I,C]; A61K0031-215 [I,A]; A61K0031-216 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0015-00 [I,C]; A61P0015-10 [I,A]; A61P0015-12 [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0025-00 [I,C]; A61P0025-08 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0309-00 [I,C]; C07C0309-24 [I,A]; C07C0309-42 [I,A]

IPCR C07C0203-00 [I,C]; C07C0203-04 [I,A]; A61K0031-21 [I,C]; A61K0031-215 [I,A]; A61K0031-216 [I,A]; A61P0001-00 [I,C]; A61P0001-04 [I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0015-00 [I,C]; A61P0015-10 [I,A]; A61P0015-12 [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A];

A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0025-00 [I,C]; A61P0025-08 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]; A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07C0309-00 [I,C]; C07C0309-24 [I,A]; C07C0309-42 [I,A]

CC 25-13 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

ST nitrosated dihydroxybenzenesulfonic acid prepn FGF1 inhibitor treatment disease

IT Amyloidosis
(- associated diseases, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Animal cell line
(3T3; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Keratosis
(actinic, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Prostate gland disease
(benign hyperplasia, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Angiogenesis
(chronic temporal lobe epilepsy- associated, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Antimicrobial agents
Antioxidants
Cholinesterase inhibitors
Endothelin receptor antagonists
Immunomodulators
NMDA receptor antagonists
Nonsteroidal anti-inflammatory drugs
(codrugs; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Retinoids
Steroids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Hydrolysis
(enzymic; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Sexual disorders
(female, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Cell proliferation
(glioma; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT Skin, disease
(hyperpigmentation, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and

prophylaxis of different diseases)
IT Sexual disorders
(impotence, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
IT Tau proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phosphorylation inhibitors, codrugs; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
IT Analgesics
Angiogenesis inhibitors
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Anticoagulants
Antifibrotic agents
Antihypertensives
Antitumor agents
Antiulcer agents
Combination chemotherapy
Cytotoxic agents
Drugs
Fibroblast
Heart rate
Hypolipemic agents
Pharmaceutical carriers
Pharmaceutical excipients
Phosphorylation
Prodrugs
Prophylaxis
Signal transduction
Vasodilators
(preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
IT Skin, disease
(rosacea, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
IT Keratosis
(seborrheic, treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)
IT Arthritis
Asthma
Atherosclerosis
Crohn disease
Dermatitis
Eye, disease
Fibrosis
Glomerulonephritis
Hemangioma
Hyperlipidemia
Hypertension
Inflammation
Neuroglia, neoplasm
Pain
Pigmentation disorders
Psoriasis
Thrombosis
Ulcerative colitis

(treatment of; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 69-72-7, Salicylic acid, biological studies 1406-16-2D, Vitamin D, analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrugs; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 1061696-45-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 1061696-48-7P 1061696-51-2P 1061696-54-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 9001-08-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor, codrugs; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 9036-21-9, Cyclic nucleotide phosphodiesterase 9068-52-4, CGMP phosphodiesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, codrugs; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 96627-32-6P 1061696-58-9P 1061696-60-3P 1061696-62-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 7665-99-8, CGMP 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 100-02-7, 4-Nitrophenol, reactions 2067-33-6, 5-Bromovaleric acid 20123-80-2, Calcium dobesilate 21799-87-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

IT 20123-80-2, Calcium dobesilate 21799-87-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of nitrosated derivs. of dihydroxybenzene compds. useful in treatment and prophylaxis of different diseases)

RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



● K

L63 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:223400 HCAPLUS Full-text
DOCUMENT NUMBER: 148:276783
TITLE: 2,5-Dihydroxybenzene for the treatment of psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz de Tejada Gorman, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: PCT Int. Appl., 66pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020030	A1	20080221	WO 2007-EP58443	20070815

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,

```
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
     ES 2315118           A1    20090316    ES 2006-2218           20060816
     ES 2315118           B1    20091230
     US 20080113947       A1    20080515    US 2007-839515         20070815
     US 20080113948       A1    20080515    US 2007-839520         20070815
     US 20080114060       A1    20080515    US 2007-839522         20070815
     US 20080125486       A1    20080529    US 2007-839525         20070815
     EP 2056814           A1    20090513    EP 2007-788429         20070815
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
             AL, BA, HR, MK, RS
     MX 2009001660        A     20090424    MX 2009-1660           20090213
PRIORITY APPLN. INFO.:                     ES 2006-2218        A  20060816
                                           ES 2007-1856        A  20070702
                                           WO 2007-EP58443     W  20070815
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):         MARPAT 148:276783
AB    The invention relates to the use of a 2,5-dihydroxybenzene derivative or a
pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in preparing a
medicinal product for the treatment and/or prophylaxis of psoriasis. IPCI A61K0031-185
[I,A]; A61K0031-192 [I,A]; A61K0031-21 [I,A]; A61K0031-216
     [I,A]; A61K0031-255 [I,A]; A61P0017-06 [I,A]; A61P0017-00 [I,C*];
     A61K0031-60 [I,A]; A61K0045-06 [I,A]; A61K0045-00 [I,C*]
IPCR A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-192 [I,A]; A61K0031-21
     [I,C]; A61K0031-21 [I,A]; A61K0031-216 [I,A]; A61K0031-255 [I,A];
     A61K0031-60 [I,C]; A61K0031-60 [I,A]; A61K0045-00 [I,C]; A61K0045-06
     [I,A]; A61P0017-00 [I,C]; A61P0017-06 [I,A]
CC   1-12 (Pharmacology)
ST   hydroxybenzene deriv psoriasis therapy
IT   Epidermal growth factor receptors
     Fibroblast growth factor receptors
     Hepatocyte growth factor
     Hepatocyte growth factor receptors
     Vascular endothelial growth factor receptors
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (antagonists; hydroxybenzene derivs. for treatment of
        psoriasis)
IT   Therapy
        (coadjuvant; hydroxybenzene derivs. for treatment of
        psoriasis)
IT   Angiogenesis inhibitors
     Anti-inflammatory agents
     Antimicrobial agents
     Antioxidants
     Antitumor agents
     Apoptosis
     Buccal drug delivery systems
     Endothelin receptor antagonists
     Fibrosis
     Human
     Immunomodulators
     Lung, neoplasm
     Neuroglia, neoplasm
     Oral drug delivery systems
     Otic drug delivery systems
     Parenteral drug delivery systems
     Photodynamic therapy
       Phototherapy
       Prodrugs
     Prophylaxis
```

Prostate gland, neoplasm
Psoriasis
Rectal drug delivery systems
Topical drug delivery systems
Transdermal drug delivery systems
(hydroxybenzene derivs. for treatment of psoriasis)

IT Corticosteroids, biological studies
Retinoids
Steroids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene derivs. for treatment of psoriasis)

IT Fibroblast
(mitogenesis; hydroxybenzene derivs. for treatment of psoriasis)

IT 62031-54-3, Fibroblast growth factor 62229-50-9, Epidermal growth factor 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydroxybenzene derivs. for treatment of psoriasis)

IT 106096-92-8, FGF-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydroxybenzene derivs. for treatment of psoriasis)

IT 59-05-2, Methotrexate 69-72-7, Salicylic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 110-17-8D, 2-Butenedioic acid (2E)-, derivs. 123-31-9D, 1,4-Dihydroxybenzene, derivs. 490-79-9, Gentisic acid 636-01-1, 2,5-Dihydroxycinnamic acid 1406-16-2D, Vitamin D, analogs 21799-87-1, Potassium 2,5-Dihydroxybenzenesulfonate 21799-87-1D, ester derivs. 51579-69-2 57775-26-5 59687-22-8 59865-13-3, Cyclosporin 60630-38-8 79122-68-2 159252-66-1 159252-66-1D, ester derivs. 170277-31-3, Infliximab 185243-69-0, Etanercept 214745-43-4, Efalizumab 222535-22-0, Alefacept 331731-18-1, Adalimumab 748106-93-6 1007839-71-5 1007839-72-6D, ester derivs. 1007839-87-3 1007839-89-5 1007839-91-9 1007839-93-1 1007839-94-2 1007839-96-4 1007840-16-5 1007840-17-6 1007840-18-7 1007840-19-8 1007840-20-1 1007840-21-2 1007840-22-3 1007840-23-4 1007840-24-5 1007849-27-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene derivs. for treatment of psoriasis)

IT 80449-02-1, Protein tyrosine kinase 141436-78-4, Protein kinase C
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; hydroxybenzene derivs. for treatment of psoriasis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 21799-87-1, Potassium 2,5-Dihydroxybenzenesulfonate 21799-87-1D, ester derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxybenzene derivs. for treatment of psoriasis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L63 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:705929 HCAPLUS Full-text
DOCUMENT NUMBER: 147:87646
TITLE: 2,5-Dihydroxybenzene sulfonate compounds for treatment of cancer, rosacea, and psoriasis
INVENTOR(S): Cuevas Sanchez, Pedro; Romero Garrido, Antonio; Gimenez Gallego, Guillermo; Valverde Lopez, Serafin; Lozano Puerto, Rosa Maria
PATENT ASSIGNEE(S): Action Medicines, S.L., Spain
SOURCE: U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of U.S. Ser. No. 588,166.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20070149618 A1 20070628 US 2006-506469 20060816
ES 2238924 A1 20050901 ES 2004-371 20040217
ES 2238924 B1 20061201
WO 2005077352 A1 20050825 WO 2005-ES70017 20050216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 20080125485 A1 20080529 US 2007-839508 20070815
US 20090111779 A1 20090430 US 2008-257854 20081024
PRIORITY APPLN. INFO.: ES 2004-371 A 20040217
WO 2005-ES70017 W 20050216
US 2006-588166 A2 20060802
ES 2006-2219 A 20060816
US 2006-506469 A2 20060816
ES 2007-1857 A 20070702
US 2008-588166 A2 20080807

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention describes compns. and methods of use for 2,5-dihydroxybenzene sulfonic acid compds. and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compns. comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compds. or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. Administration of 2,5-dihydroxybenzene sulfonate combined with irinotecan reduced the tumor progression of gliomas in rats to a greater degree than treatment of either agent alone.

INCL 514553000; 514171000; 514559000; 514167000; 514159000
IPCI A61K0031-185 [I,A]; A61K0031-60 [I,A]; A61K0031-59 [I,A]; A61K0031-56 [I,A]
IPCR A61K0031-185 [I,C]; A61K0031-185 [I,A]; A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61K0031-59 [I,C]; A61K0031-59 [I,A]; A61K0031-60 [I,C]; A61K0031-60 [I,A]
NCL 514/553.000; 514/159.000; 514/167.000; 514/171.000; 514/559.000
CC 1-6 (Pharmacology)
ST dihydroxybenzene sulfonate cancer rosacea psoriasis therapy; glioma irinotecan dihydroxybenzene sulfonate antitumor combination
IT Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Buccal drug delivery systems
Chemosensitizers, pharmaceutical
Chemotherapy
Combination chemotherapy
Cytotoxic agents

Dermatological agents
Immunomodulators
Inhalation drug delivery systems
Leukemia
Melanoma
NMDA receptor antagonists
Neuroglia, neoplasm
Oral drug delivery systems
Parenteral drug delivery systems
Pharmaceutical carriers
Pharmaceutical creams
Proliferation inhibition
Psoriasis
Rectal drug delivery systems
Skin, neoplasm
Topical drug delivery systems
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Retinoids
Steroids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
Skin, neoplasm
(Bowen's disease, verrucae; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Keratosis
(actinic; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Apoptosis
(basal cell carcinoma cells; 2,5-dihydroxybenzenesulfonate-induced; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(basal cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
(basal cell; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Carcinoma
(cutaneous squamous cell; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Antitumor agents
Immunotherapy
Radiotherapy
(efficacy; agents improving; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(keratoacanthoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Sarcoma
(orangiosarcoma; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Drug interactions
(pharmacodynamic, potentiation; 2,5-dihydroxybenzene

sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, disease
(rosacea; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Neoplasm
(solid; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT Skin, neoplasm
(squamous cell carcinoma; 2,5-dihydroxybenzene sulfonate compds. for treatmeot of cancer, rosacea and psoriasis)

IT Paraffin waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(white soft; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 51-21-8, 5-Fluorouracil 57-22-7, Vincristine 69-72-7, Salicylic acid, biological studies 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 1406-16-2D, Vitamin D, analog 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 15663-27-1, Cisplatin 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 33069-62-4, Paclitaxel 68864-98-2, 2,5-Dihydroxybenzenesulfonate 97225-83-7, Magnesium 2,5-dihydroxybenzenesulfonate 97682-44-5, Irinotecan 100286-90-6, Campto
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 112-92-5, Stearic alcohol 7732-18-5, Water, biological studies 36653-82-4, Cetylic alcohol 942134-54-5, Sorbinate deato
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 116243-73-3, Endothelin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist; 2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

IT 88-46-0, 2,5-Dihydroxybenzenesulfonic acid 2624-44-4, Diethylamine 2,5-dihydroxybenzenesulfonate 20123-80-2, Calcium 2,5-dihydroxybenzenesulfonate 21799-87-1, Potassium 2,5-dihydroxybenzenesulfonate 68864-98-2, 2,5-Dihydroxybenzenesulfonate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2,5-dihydroxybenzene sulfonate compds. for treatment of cancer, rosacea and psoriasis)

RN 88-46-0 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy- (CA INDEX NAME)



RN 2624-44-4 HCAPLUS

CN Benzenesulfonic acid, 2,5-dihydroxy-, compd. with N-ethylethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 109-89-7
CMF C4 H11 N

CM 2

CRN 88-46-0
CMF C6 H6 O5 S



RN 20123-80-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

RN 21799-87-1 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, potassium salt (1:1) (CA INDEX NAME)



RN 68864-98-2 HCAPLUS
CN Benzenesulfonic acid, 2,5-dihydroxy-, ion(1-) (CA INDEX NAME)



L63 ANSWER 7 OF 8 WPIX COPYRIGHT 2010 THOMSON REUTERS on STN
ACCESSION NUMBER: 2008-N22597 [200877] WPIX
TITLE: New cinnamic amide derivative useful for treating diseases responsive to modulation of potassium channel, e.g., respiratory diseases, convulsion, erectile dysfunction, gastrointestinal dysfunction, ischemia, schizophrenia and sleep disorder
DERWENT CLASS: B05
INVENTOR: CHRISTOPHERSEN P; DEMNITZ J; GRUNNET M; JENSEN T; JENSEN T D; JONES D; JONES D S; MADSEN L; MADSEN L S; NARDI A; NIELSEN E; NIELSEN E O; STROBAK D; STROBAEK D
PATENT ASSIGNEE: (NURO-C) NEUROSEARCH AS
COUNTRY COUNT: 121

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2008074755	A2	20080626	(200877)*	EN	45[1]	
WO 2008074755	A3	20081002	(200877)	EN		
EP 2121569	A2	20091125	(200978)	EN		
US 20100087496	A1	20100408	(201024)	EN		
JP 2010513387	W	20100430	(201029)	JA	47	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2008074755	A2	WO 2007-EP64015	20071217
US 20100087496	A1 Provisional	US 2006-870781P	20061219
EP 2121569	A2	EP 2007-857649	20071217

EP 2121569 A2 PCT Application	WO 2007-EP64015	20071217
US 20100087496 A1 PCT Application	WO 2007-EP64015	20071217
US 20100087496 A1	US 2009-519683	20090724
JP 2010513387 W PCT Application	WO 2007-EP64015	20071217
JP 2010513387 W	JP 2009-542019	20071217

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 2121569	A2	Based on	WO 2008074755	A
JP 2010513387	W	Based on	WO 2008074755	A

PRIORITY APPLN. INFO: DK 2007-481 20070328
DK 2006-1657 20061218
US 2006-870781P 20061219

AB WO 2008074755 A2 UPAB: 20091126

NOVELTY - A cinnamic amide derivative (I), is new.

DETAILED DESCRIPTION - A cinnamic amide derivative of formula (I), or its enantiomer, mixture of its enantiomers, or salt, is new.

R1=nitro, amino, hydroxy, carboxy, sulfonic acid, sulfonic acid alkyl ester, sulfamoyl, acetamido, methyl-sulfonyl-amino, phenyl-sulfonyl-amino, N-methyl-sulfonyl-carboxamide (methyl-sulfonyl-amino-carbonyl), N-phenyl-sulfonyl-carboxamide (phenyl-sulfonyl-amino-carbonyl), trifluoromethyl-sulfonyl-amino, trifluoromethyl-acetyl-amino, 2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl- ethyl, tetrazolyl, tetrazolyl-methoxy, 5-oxo-4,5-dihydro-(1,2,4)oxadiazol-3-yl or N-cyano-carboxamide;

R2 and R3=phenyl (optionally substituted with halo and/or trifluoromethyl), H, halo, trifluoromethyl, or hydroxy;

R4 and R5=H, halo, trifluoromethyl, nitro and/or phenyl;or

R4 and R5 together with the aromatic ring to which they are attached=benzo-fused carbocyclic aromatic ring;

R' and R'a=H;or

R' and R'a together with the carbon atoms of the aromatic ring to which they are attached=bicyclic carbocyclic or heterocyclic ring selected from 2H-chromenyl (optionally substituted with oxo to form a 2-oxo-2H-chromenyl derivative), or indolyl.

INDEPENDENT CLAIMS are included for the following:

(1) use of a combination of a cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; or their salts, for the manufacture of a medicament for the treatment or alleviation of sexual dysfunction; and

(2) a kit of parts comprising at least two separate unit dosage forms cinnamic amide derivative (I); and a phosphodiesterase inhibitor; or an agent that potentiates endothelium-derived hyperpolarizing factor-mediated responses; and optionally instructions for the simultaneous, sequential or separate administration of the cinnamic amide derivative (I), and the phosphodiesterase inhibitor, or the agent, to a patient.

ACTIVITY - Respiratory-Gen.; Anticonvulsant; Vasotropic; Cardiant; CNS-Gen.; Muscular-Gen.; Nephrotropic; Uropathic; Hepatotropic; Gastrointestinal-Gen.; Laxative; Antidiarrheic; Cerebroprotective; Vulnerary; Antianginal; Antiparkinsonian; Neuroleptic; Nootropic; Tranquilizer; Antidepressant; Antimanic; Neuroprotective; Analgesic; Gynecological; Hypnotic; Immunosuppressive; Antiarrhythmic; Cardiovascular-Gen.; Hypotensive; Relaxant; Antidiabetic; Tocolytic; Cytostatic; Antiinflammatory; Auditory; Antimigraine; Endocrine-gen.; Ophthalmological; Osteopathic; Angiogenesis-inhibitor; Antiarthritic; Antirheumatic; Antipsoriatic; Antianemic.

MECHANISM OF ACTION - Ion channel modulator e.g. calcium activated potassium (BK) channel modulator. (E)-N-(5-chloro-2-(1H-tetrazol-5-yl)- phenyl)-3-naphthalen-2-yl-acrylamide (I') was tested for BK channel opening activity using BK channels heterologously expressed in Xenopus laevis oocytes in terms of current. BK current

was activated by repeated step protocols. The compound (I') (1 mu M) was added. The compound (I') showed marked increased in current of 6-9 mu M at 80-134 seconds.

USE - In the manufacture of a pharmaceutical composition/medicament for treating respiratory disease, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, motor neuron diseases, myokymia, renal disorders, polycystic kidney disease, bladder hyperexcitability, bladder spasms, urinogenital disorders, urinary incontinence, bladder outflow obstruction, erectile dysfunction, gastrointestinal dysfunction, gastrointestinal hypomotility disorders, gastrointestinal motility insufficiency, postoperative ileus, constipation, gastroesophageal reflux disorder, secretory diarrhea, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, ataxia, traumatic brain injury, stroke, Parkinson's disease, bipolar disorder, psychosis, schizophrenia, autism, anxiety, mood disorders, depression, manic depression, psychotic disorders, dementia, learning deficiencies, age related memory loss, memory and attention deficits, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dysmenorrhea, narcolepsy, sleeping disorders, sleep apnea, Raynaud's disease, intermittent claudication, Sjogren's syndrome, xerostomia, arrhythmia, cardiovascular disorders, hypertension, myotonic dystrophy, myotonic muscle dystrophia, spasticity, xerostomia, diabetes Type II, hyperinsulinemia, premature labor, cancer, brain tumors, inflammatory bowel disease, irritable bowel syndrome, colitis, colitis Crohn', immune suppression, hearing loss, migraine, pain, neuropathic pain, inflammatory pain, trigeminal neuralgia, vision loss, rhinorrhoea, ocular hypertension (glaucoma), baldness, cardiac arrhythmia, atrial arrhythmia, ventricular arrhythmia, atrial fibrillation, ventricular fibrillation, tachyarrhythmia, atrial tachyarrhythmia, ventricular tachyarrhythmia, bradyarrhythmia, or any other abnormal rhythm, e.g. caused by myocardial ischemia, myocardial infarction, cardiac hypertrophy or cardiomyopathy disease/disorder/condition responsive to modulation of potassium channel in a mammal including a human, and for treating sexual dysfunction i.e. male dysfunction and female dysfunction (claimed); and also for treating diseases such as bone metabolic disease, disease that is responsive to inhibition of angiogenesis, an ophthalmic angiogenesis related diseases, rheumatoid arthritis, psoriasis and sickle-cell anemia, and pain.

ADVANTAGE - The compound are potent ion channel modulator and treats disease, disorder or condition responsive to modulation of potassium channels without any harmful side effects. The compounds show calcium activated potassium channel opening activity in sub-micromolar and micromolar range, i.e., from below 1-100 mu M.

AN.S DCR-89832
CN.P CALCIUM DOBESILATE
CN.S Calcium; 2,5-dihydroxy-benzenesulfonate
SDCN R20556

CM 1

Ca

CM 2



L63 ANSWER 8 OF 8 WPIX COPYRIGHT 2010 THOMSON REUTERS on STN
ACCESSION NUMBER: 1996-020345 [199602] WPIX
DOC. NO. CPI: C1996-006976 [199602]
TITLE: Opiate antagonist and calcium salt in compsn. - for treatment of endorphin-mediated pathologies
DERWENT CLASS: B05; C03
INVENTOR: CIORCI R L; MINOIA P; SCIORSCI R L
PATENT ASSIGNEE: (CIOR-I) CIORCI R L; (MINO-I) MINOIA P; (RAPH-I) RAPHAEL L G; (SCIO-I) SCIORSCI R; (SCIO-I) SCIORSCI R L; (EXCE-N) EXCELSIOR LIFE SCI IRELAND LTD
COUNTRY COUNT: 64

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9531985	A2	19951130	(199602)*	EN	19[0]	
AU 9526149	A	19951218	(199611)	EN		
WO 9531985	A3	19960104	(199622)	EN		
EP 760661	A1	19970312	(199715)	EN	[0]	
IT 1269826	B	19970415	(199744)	IT		
JP 10500423	W	19980113	(199812)	JA	19[0]	
KR 97703148	A	19970703	(199829)	KO		
US 5811451	A	19980922	(199845)	EN		
HU 77920	T	19981028	(199850)	HU		
EP 760661	B1	19981230	(199905)	EN		
DE 69507029	E	19990211	(199912)	DE		
ES 2128735	T3	19990516	(199926)	ES		
AU 708778	B	19990812	(199944)	EN		
CN 1151116	A	19970604	(200131)	ZH		
CN 1083264	C	20020424	(200519)	ZH		
JP 2007210995	A	20070823	(200757)	JA	11	
CA 2190943	C	20100622	(201045)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9531985	A2	WO 1995-EP1931	19950522
IT 1269826	B	IT 1994-MI1048	19940524
AU 9526149	A	AU 1995-26149	19950522
AU 708778	B	AU 1995-26149	19950522
CN 1151116	A	CN 1995-193758	19950522
CN 1083264	C	CN 1995-193758	19950522
DE 69507029	E	DE 1995-69507029	19950522
EP 760661	A1	EP 1995-920851	19950522
EP 760661	B1	EP 1995-920851	19950522
DE 69507029	E	EP 1995-920851	19950522
ES 2128735	T3	EP 1995-920851	19950522
JP 10500423	W	JP 1995-530058	19950522
JP 2007210995	A Div Ex	JP 1995-530058	19950522
WO 9531985	A3	WO 1995-EP1931	19950522
EP 760661	A1	WO 1995-EP1931	19950522
JP 10500423	W	WO 1995-EP1931	19950522
KR 97703148	A	WO 1995-EP1931	19950522
US 5811451	A	WO 1995-EP1931	19950522
HU 77920	T	WO 1995-EP1931	19950522
EP 760661	B1	WO 1995-EP1931	19950522
DE 69507029	E	WO 1995-EP1931	19950522

HU 77920 T	HU 1996-3228 19950522
KR 97703148 A	KR 1996-706602 19961121
US 5811451 A	US 1996-737902 19961121
JP 2007210995 A	JP 2006-303392 20061108
CA 2190943 C	CA 1995-2190943 19950522
CA 2190943 C PCT Application	WO 1995-EP1931 19950522

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
AU 708778	B	Previous Publ	AU 9526149	A
DE 69507029	E	Based on	EP 760661	A
ES 2128735	T3	Based on	EP 760661	A
AU 9526149	A	Based on	WO 9531985	A
EP 760661	A1	Based on	WO 9531985	A
JP 10500423	W	Based on	WO 9531985	A
KR 97703148	A	Based on	WO 9531985	A
US 5811451	A	Based on	WO 9531985	A
HU 77920	T	Based on	WO 9531985	A
EP 760661	B1	Based on	WO 9531985	A
DE 69507029	E	Based on	WO 9531985	A
AU 708778	B	Based on	WO 9531985	A
CA 2190943	C	Based on	WO 9531985	A

PRIORITY APPLN. INFO: IT 1994-MI1048 19940524

AB WO 1995031985 A2 UPAB: 20050702

A pharmaceutical compsn. essentially comprises an opiate antagonist and a calcium salt.

USE - The compsn. is for the treatment of endorphin-mediated pathologies, including diseases of the CNS e.g. paraplegia, nervous conducibility disturbances, Alzheimer's disease, cerebral ischaemia and multiple sclerosis; gastrointestinal diseases such as ulcers and irritable bowel syndrome; cardiovascular diseases such as infarct and septic shock; dermatological diseases such as vitiligo, psoriasis, alopecia, dermatitis, traumatic injuries and burns; endocrinological and genitourinary diseases such as LUF syndrome, ovaric micropolyaptosis, impotence, hyperprolattinemia, hypophysary dwarfism, interstitial cystitis and primary amenhorrea; and also inflammatory conditions; infectious diseases, diseases of the muscle-skeletal system such as osteoporosis, arthritis, ostitis, periostitis, myopathies and autoimmune diseases; also, in veterinary medicine, the treatment of puerperal shock in bovines, viral diseases in dogs and cats, MMA syndrome, Mulberry's heart disease, ruminal meteorism, Hoflund syndrome and osteo-articular traumas, and also for controlling reproductive activity in mammals, fish and birds, for inducing the lysis of the corpus luteum, to improve athletic performance in horses and dogs; and in contraception.

AN.S DCR-89832
CN.P CALCIUM DOBESILATE
CN.S Calcium; 2,5-dihydroxy-benzenesulfonate
SDCN R20556

CM 1

Ca

CM 2


O
O
O
S
O
O

SEARCH HISTORY

```
     FILE 'HCAPLUS' ENTERED AT 16:42:29 ON 22 JUL 2010
                E US2008-588166/APPS
L1             3 SEA SPE=ON  ABB=ON  PLU=ON  US2008-588166/APPS
                D SCAN

     FILE 'REGISTRY' ENTERED AT 16:43:18 ON 22 JUL 2010
L2             STRUCTURE UPLOADED
                D
L3            23 SEA SSS SAM L2
L4           575 SEA SSS FUL L2
L5             STRUCTURE UPLOADED
                D
L6            23 SEA SUB=L4 SSS SAM L5
L7           569 SEA SUB=L4 SSS FUL L5

     FILE 'HCAPLUS' ENTERED AT 16:47:38 ON 22 JUL 2010
L8          1313 SEA SPE=ON  ABB=ON  PLU=ON  L7
L9         21558 SEA SPE=ON  ABB=ON  PLU=ON  PSORIASIS+PFT/CT OR (?PSORIASIS?
                OR ?PUSTULOSIS?)/BI
L10            6 SEA SPE=ON  ABB=ON  PLU=ON  L8 AND L9
L11          553 SEA SPE=ON  ABB=ON  PLU=ON  L8 AND ((BAC OR DMA OR PAC OR PKT
                OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR ?TREAT?)/BI)
L12            6 SEA SPE=ON  ABB=ON  PLU=ON  L11 AND L9
L13            6 SEA SPE=ON  ABB=ON  PLU=ON  L10 OR L12

     FILE 'REGISTRY' ENTERED AT 16:54:16 ON 22 JUL 2010
L14            1 SEA SPE=ON  ABB=ON  PLU=ON  "2,5-DIHYDROXYBENZENESULFONIC
                ACID"/CN

     FILE 'HCAPLUS' ENTERED AT 16:58:43 ON 22 JUL 2010
L15          181 SEA SPE=ON  ABB=ON  PLU=ON  L14
L16           68 SEA SPE=ON  ABB=ON  PLU=ON  L15 AND ((BAC OR DMA OR PAC OR PKT
                OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR ?TREAT?)/BI)
L17            5 SEA SPE=ON  ABB=ON  PLU=ON  L16 AND L9
L18            6 SEA SPE=ON  ABB=ON  PLU=ON  L13 OR L17

     FILE 'REGISTRY' ENTERED AT 16:59:51 ON 22 JUL 2010
                E "2,5-DIHYDROXYBENZENESULFONIC ACID"/CN
L19            4 SEA SPE=ON  ABB=ON  PLU=ON  ("2,5-DIHYDROXYBENZENESULFONIC
                ACID CALCIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                DIETHYLAMINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                MONOSODIUM SALT"/CN OR "2,5-DIHYDROXYBENZENESULFONIC ACID
                MONOTOSYLATE MORPHOLINE SALT"/CN OR "2,5-DIHYDROXYBENZENESULFON
                IC ACID SODIUM SALT"/CN)

     FILE 'HCAPLUS' ENTERED AT 17:00:36 ON 22 JUL 2010
L20          494 SEA SPE=ON  ABB=ON  PLU=ON  L19
L21          359 SEA SPE=ON  ABB=ON  PLU=ON  L20 AND ((BAC OR DMA OR PAC OR PKT
                OR THU)/RL OR (?THERA? OR ?PHARM? OR ?DRUG? OR ?TREAT?)/BI)
L22            4 SEA SPE=ON  ABB=ON  PLU=ON  L21 AND L9
L23            6 SEA SPE=ON  ABB=ON  PLU=ON  L22 OR L18
L24         2346 SEA SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L25          205 SEA SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L26           71 SEA SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L27         2879 SEA SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L28            1 SEA SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L29            0 SEA SPE=ON  ABB=ON  PLU=ON  L23 AND ((L24 OR L25 OR L26 OR L27
```

```
                OR L28))
L30           3 SEA SPE=ON  ABB=ON  PLU=ON  L1 AND L23
L31           0 SEA SPE=ON  ABB=ON  PLU=ON  L8 AND ((L24 OR L25 OR L26 OR L27
                OR L28))
L32           0 SEA SPE=ON  ABB=ON  PLU=ON  L24 AND L25 AND L26 AND L27 AND
                L28
L33           5 SEA SPE=ON  ABB=ON  PLU=ON  L24 AND ((L25 OR L26 OR L27 OR
                L28))
L34           0 SEA SPE=ON  ABB=ON  PLU=ON  L25 AND ((L26 OR L27 OR L28))
L35           0 SEA SPE=ON  ABB=ON  PLU=ON  L26 AND ((L27 OR L28))
L36           0 SEA SPE=ON  ABB=ON  PLU=ON  L27 AND L28
                D SCAN L33 TI

     FILE 'WPIX' ENTERED AT 17:06:19 ON 22 JUL 2010
L37           4 SEA SSS SAM L5
L38          31 SEA SSS FUL L5
L39          99 SEA SPE=ON  ABB=ON  PLU=ON  L38/DCR
L40           4 SEA SPE=ON  ABB=ON  PLU=ON  L39 AND (?PSORIASIS? OR ?PUSTULOSIS
                ?)
L41         113 SEA SPE=ON  ABB=ON  PLU=ON  SANCHEZ P?/AU
L42          21 SEA SPE=ON  ABB=ON  PLU=ON  GARRIDO A?/AU
L43          13 SEA SPE=ON  ABB=ON  PLU=ON  GALLEGO G?/AU
L44         142 SEA SPE=ON  ABB=ON  PLU=ON  LOPEZ S?/AU
L45           8 SEA SPE=ON  ABB=ON  PLU=ON  PUERTO R?/AU
L46           0 SEA SPE=ON  ABB=ON  PLU=ON  L40 AND ((L41 OR L42 OR L43 OR L44
                OR L45))
L47           0 SEA SPE=ON  ABB=ON  PLU=ON  L41 AND L42 AND L43 AND L44 AND
                L45
L48           2 SEA SPE=ON  ABB=ON  PLU=ON  L41 AND ((L42 OR L43 OR L44 OR
                L45))
L49           1 SEA SPE=ON  ABB=ON  PLU=ON  L42 AND ((L43 OR L44 OR L45))
L50           1 SEA SPE=ON  ABB=ON  PLU=ON  L43 AND ((L44 OR L45))
L51           0 SEA SPE=ON  ABB=ON  PLU=ON  L44 AND L45
L52           2 SEA SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50)

     FILE 'BEILSTEIN' ENTERED AT 17:11:11 ON 22 JUL 2010
L53           6 SEA SSS SAM L5
L54         137 SEA SSS FUL L5
L55          17 SEA SPE=ON  ABB=ON  PLU=ON  L54 AND BABSAN/FA
                SEL BABSAN L55

     FILE 'BABS' ENTERED AT 17:12:38 ON 22 JUL 2010
L56          34 SEA SPE=ON  ABB=ON  PLU=ON  (5779456/BABSAN OR 5795277/BABSAN
                OR 5824898/BABSAN OR 5514361/BABSAN OR 5640811/BABSAN OR
                5663724/BABSAN OR 5513340/BABSAN OR 5650706/BABSAN OR 5661677/B
                ABSAN OR 5664312/BABSAN OR 5683633/BABSAN OR 5716795/BABSAN OR
                5720015/BABSAN OR 5721112/BABSAN OR 5729262/BABSAN OR 5735774/B
                ABSAN OR 5742821/BABSAN OR 5795962/BABSAN OR 5821526/BABSAN OR
                5823978/BABSAN OR 5833257/BABSAN OR 5834887/BABSAN OR 5864226/B
                ABSAN OR 5883193/BABSAN OR 6272676/BABSAN OR 6307749/BABSAN OR
                6456010/BABSAN OR 6467490/BABSAN OR 6487461/BABSAN OR 6491941/B
                ABSAN OR 6536509/BABSAN OR 6574272/BABSAN OR 6575150/BABSAN OR
                6607291/BABSAN OR 6649109/BABSAN)
L57           0 SEA SPE=ON  ABB=ON  PLU=ON  L56 AND (PSORIASIS? OR PUSTULOSIS?)

     FILE 'BEILSTEIN' ENTERED AT 17:16:22 ON 22 JUL 2010
L58         120 SEA SPE=ON  ABB=ON  PLU=ON  L54 NOT L55
L59          67 SEA SPE=ON  ABB=ON  PLU=ON  L58 AND (PRY<=2004 OR AY<=2004 OR
                PY<=2004 OR PD<=2004)
                D IDE
```

```
     FILE 'REGISTRY' ENTERED AT 17:21:41 ON 22 JUL 2010

     FILE 'HCAPLUS' ENTERED AT 17:21:44 ON 22 JUL 2010
               D STAT QUE L33

     FILE 'WPIX' ENTERED AT 17:21:54 ON 22 JUL 2010
               D STAT QUE L52

     FILE 'HCAPLUS, WPIX' ENTERED AT 17:22:10 ON 22 JUL 2010
L60            7 DUP REMOVE L33 L52 (0 DUPLICATES REMOVED)
                     ANSWERS '1-5' FROM FILE HCAPLUS
                     ANSWERS '6-7' FROM FILE WPIX
               D L60 IBIB ABS HITIND HITSTR 1-5
               D L60 IBIB AB HITSTR 6-7

     FILE 'HCAPLUS' ENTERED AT 17:22:51 ON 22 JUL 2010
               D STAT QUE L23
L61            6 SEA SPE=ON  ABB=ON  PLU=ON  L23 NOT L33

     FILE 'WPIX' ENTERED AT 17:23:02 ON 22 JUL 2010
               D STAT QUE L40
L62            4 SEA SPE=ON  ABB=ON  PLU=ON  L40 NOT L52

     FILE 'HCAPLUS, WPIX' ENTERED AT 17:23:38 ON 22 JUL 2010
L63            8 DUP REMOVE L61 L62 (2 DUPLICATES REMOVED)
                     ANSWERS '1-6' FROM FILE HCAPLUS
                     ANSWERS '7-8' FROM FILE WPIX
               D L63 IBIB ABS HITIND HITSTR 1-6
               D L63 IBIB AB HITSTR 7-8

=>


Uploading 10588166.str
```




```
chain nodes :
7  8  9  10  11  12
ring nodes :
1  2  3  4  5  6
chain bonds :
1-12  4-11  6-7  7-8  7-9  7-10
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  1-12  2-3  3-4  4-5  4-11  5-6  6-7  7-8  7-9  7-10


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS
```

Uploading LL5.str



chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
chain bonds :
1-12 4-11 6-7 7-8 7-9 7-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-12 4-11 6-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-9 7-10

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS